This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Virios Therapeutics’s 8K filing here.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Articles
- Five stocks we like better than Virios Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
- P/E Ratio Calculation: How to Assess Stocks
- 3 ETFs With Low Fees and Market-Beating Returns
- What is the Dogs of the Dow Strategy? Overview and Examples
- Inflation Threats Make Yield Curve ETFs a Top Trade
